38 Matching Annotations
  1. Jun 2025
    1. seems to have more often then not an associated Days Supplied, but those with procedure codes rely on

      Calculate their estimate weight from first claim date we observe. That should be closest to most normal dose

  2. May 2025
    1. atients Characteristics - 6 months CE Pre & 2 Post

      Look at this population.

      look at gaps between dosing that these patients are receiving alt. Do we have the time between dosing getting lower.

  3. Mar 2025
  4. Feb 2025
  5. Jan 2025
  6. Apr 2024
    1. osing Information on Venentoclax Patients

      Arliene and Sophia: We only have 273 of our patients with a record in the Medication orders table. Not everyone is represented.

  7. Dec 2023
  8. Nov 2023
    1. N of Patient Eyes (1 or 2 Treated)

      David, here is the context. We have 83% of patients being treated for both eyes. That will mean that the N of injections probably appears higher since we aren't breaking them down into injections by specific eye.

  9. Oct 2023
    1. Our final sample size for the CLL FlatIron data set is 5,108 CLL patients fitting our inclusion and exclusion criteria.

      Final sample size for our study

  10. Sep 2023
    1.     Medicare Cost 497 (0.9%) 1,005 (1.8%)     Medicare Risk 3,136 (5.4%) 4,952 (9.0%)

      Slightly higher Medicare Cost and Risk patients in the Race/Ethnicity grouping. Possibly due to the older age

    1. Ultimately, after consulting with my TI colleagues and reviewing what we need to do for variable follow-up, I believe that for ease of interpretability that we should use the 6 months CE pre patients only for this analysis.

      Can you clarify?